A Randomized, Double-Blind, Placebo-Controlled, Single-Center Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of HST101 in Healthy Chinese Study Participants With Elevated LDL-C Levels This is a single-center, randomized, double-blin...
-In July 2018, we acquired an Austin, Texas based clinical research CRO WuXi Clinical Development, Inc. (carrying on business as ResearchPoint Global). This acquisition has allowed us to expand our global clinical trial services offering to both China based companies and US based companies for th...
Shorten clinical development timeline using novel GPEx® Lightning cell line development technology. Immediate Availability of All Protein A Resins Purolite July 14th 2023 Article Accelerate your downstream purification with high yield, high recovery & fewer cycles and a faster route to market. Introduc...
From 2007 to 2010, he served as the president of research and development in Asia and vice president of global research and development of Pfizer Inc. (stock code: PFE.NYSE) in the United States. From 2011 to 2014, he was the vice president of Asia and Emerging Markets iMed Research and...
(Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through ...
the discovery, development, and commercialization of novel biologics, today announced financial results for the six months ended June 30, 2022, and provided key business updates. Figure 1. Clinical efficacy of lemzoparlimab and AZA combination in MDS patients who received initial dose over six ...
will provide fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. This synergy will empower clients of both parties to accelerate PCC (Pre-clinical candidates) selection further, develop more next-generation ADCs and other bioconjug...
WuXi Biologics, a global company with leading open-access biologics technology platforms, and OncoC4 Inc, a private clinical-stage biopharmaceutical company, announced that the companies have entered into an exclusive contract development and manufacturing partnership for OncoC4's full pipeline of biolog...
Hospital Equipment Manufacturing Co., JaincoLab, National Analytical Corp., Naugra Export, Starlab International GmbH, TENAK AS, Thermo Fisher Scientific Inc., Wildcat Wholesale LLC, and Wuxi NEST Biotechnology Co. Ltd. and others. Company Offerings - Cryo Box Market - Segmentation Assessment Segmen...
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following e...